Does ELACESTRANT Cause Tumour marker increased? 222 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 222 reports of Tumour marker increased have been filed in association with ELACESTRANT (ORSERDU). This represents 3.2% of all adverse event reports for ELACESTRANT.
222
Reports of Tumour marker increased with ELACESTRANT
3.2%
of all ELACESTRANT reports
3
Deaths
21
Hospitalizations
How Dangerous Is Tumour marker increased From ELACESTRANT?
Of the 222 reports, 3 (1.4%) resulted in death, 21 (9.5%) required hospitalization, and 2 (0.9%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ELACESTRANT. However, 222 reports have been filed with the FAERS database.
What Other Side Effects Does ELACESTRANT Cause?
Nausea (1,454)
Fatigue (1,081)
Disease progression (777)
Vomiting (662)
Diarrhoea (540)
Death (499)
Drug ineffective (478)
Constipation (389)
Product dose omission issue (364)
Decreased appetite (363)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
EVEROLIMUS (228)
OLAPARIB (171)
ANASTROZOLE (142)
Which ELACESTRANT Alternatives Have Lower Tumour marker increased Risk?
ELACESTRANT vs ELAFIBRANOR
ELACESTRANT vs ELAGOLIX
ELACESTRANT vs ELAGOLIX\ESTRADIOL\NORETHINDRONE
ELACESTRANT vs ELAPEGADEMASE-LVLR
ELACESTRANT vs ELASOMERAN